In addition, high levels of SPTBN2 expression have been significantly associated with poor prognosis in both lung adenocarcinoma (LUAD), breast cancer (BC), bladder urothelial carcinoma (BLCA), colon adenocarcinoma/rectum adenocarcinoma esophageal carcinoma (COADREAD) and uterine corpus endometrial carcinoma (UCEC)13–16. This evidence concerns the gene SPTBN2 and breast cancer.